Cmv pp65 peptide-pulsed autologous dc vaccine
Cmv pp65 peptide-pulsed autologous dc vaccine - a cell-based cancer vaccine composed of autologous dendritic cells (dcs) pulsed with the human cytomegalovirus (cmv) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the cmv pp65 peptide-pulsed autologous dc vaccine exposes the immune system to the cmv pp65 peptide, which may result in a cytotoxic t-lymphocyte (ctl) response against cmv pp65-expressing tumor cells leading to cell lysis. The cmv pp65 protein, also called the 65 kda lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of cmv and is expressed in certain tumor types, such as glioblastoma. See cmv pp65 peptide-pulsed autologous dendritic cell vaccine
Latest articles Cmv pp65 peptide-pulsed autologous dc vaccine
|This medical article is a stub. You can help WikiMD by expanding it.|
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Cmv pp65 peptide-pulsed autologous dc vaccine for any updates.